Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
about
Melanized fungi in human diseaseExploiting Fungal Virulence-Regulating Transcription Factors As Novel Antifungal Drug TargetsCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsFlucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungalAlteration of enzyme specificity by computational loop remodeling and designDevelopment of Saccharomyces cerevisiae as a model pathogen. A system for the genetic identification of gene products required for survival in the mammalian host environmentQuantitative and qualitative analyses of the cell death process in Candida albicans treated by antifungal agentsYeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesisQuantitative and qualitative analysis of the antifungal activity of allicin alone and in combination with antifungal drugsFitness trade-offs restrict the evolution of resistance to amphotericin BNew Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiaeA Phytase-Based Reporter System for Identification of Functional Secretion Signals in BifidobacteriaNLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised LearningA Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast CancerEvaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancerResistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypesNovel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophagesAge and Gender Affect the Composition of Fungal Population of the Human Gastrointestinal TractEpidemiology of invasive candidiasis: a persistent public health problemGMP Synthase Is Required for Virulence Factor Production and Infection by Cryptococcus neoformans.Large-scale reverse docking profiles and their applications.Antifungal application of nonantifungal drugsInclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies.5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.Caspofungin: a potential cause of reversible severe thrombocytopenia.Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy.Clinical pharmacokinetics of oral controlled-release 5-fluorocytosineThe transposon impala is activated by low temperatures: use of a controlled transposition system to identify genes critical for viability of Aspergillus fumigatusDistinct and redundant roles of protein tyrosine phosphatases Ptp1 and Ptp2 in governing the differentiation and pathogenicity of Cryptococcus neoformans.Candida infections and their prevention.Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae.A case of chromoblastomycosis with an unusual clinical manifestation caused by Phialophora verrucosa on an unexposed area: treatment with a combination of amphotericin B and 5-flucytosine.Deletion of the uracil permease gene confers cross-resistance to 5-fluorouracil and azoles in Candida lusitaniae and highlights antagonistic interaction between fluorinated nucleotides and fluconazole.Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.Rationale for combination antifungal therapy.Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity.New developments in chemotherapy for non-invasive fungal infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
P2860
Q24633163-21991F04-BD09-41D3-A627-1809AC95C15BQ26800255-1FDEAFB9-0B49-4F3E-B6A8-4A501065A5A5Q26863344-1D25AB52-BDE8-43A1-98F8-6FB5CEE0FE7FQ27012487-F51DB8D3-12BD-4AD2-B5C0-790047C8F1B7Q27655618-16F21294-AC7B-4599-9618-8FEC979A6946Q28362118-8E31C69A-E072-4D71-834F-7216C24B1734Q28478335-0C67C280-F590-458D-9A1A-FA1C63F47048Q28481716-438D1465-B400-4160-A5E8-0530C236C26DQ28484112-FF1FF712-CDA5-4313-A662-0F4EB020F8B4Q28534687-D2F02330-7F10-4158-A7B3-0C6C583E6C03Q28547198-9772C8FD-48F7-4657-A4F6-AC37945B91E9Q28548451-88E59733-928C-4133-91ED-4651B5673B2EQ28552626-DD21095E-9244-46CD-8134-A5C15C0DCE13Q28554086-92C3A570-AF3E-46C3-96B6-B8BFA1EB5A37Q28729144-B007A409-DE96-400C-B13D-9B3FBB0A816EQ28731332-B71453B8-4FAC-4924-8D2E-D06909DDE1C5Q28830321-18310199-5F64-46DC-AA81-55DE6EF6F3AFQ28831500-101A65C7-0C7C-4CA8-B6CE-D430ECB43948Q29616758-FB4353F4-F46B-4E15-92D5-E17BCD65A220Q30397156-9162D17A-1597-4E8A-A63E-94F5B09AF5D9Q30425422-9033E722-DEC6-4973-890F-89998080C735Q30433553-34869D9F-4A58-4FCF-8D02-BCEBB3920B7AQ30907922-F033E332-5B80-4128-A447-4118C2834575Q33341541-2C597A3B-97D4-4F0A-A072-49A6D98E53C5Q33364370-D168BD20-44BB-4623-B19B-E39C66C6103CQ33424943-9D4F533F-7BE3-42F4-8E6F-46326D0481B6Q33676182-7A4C05BF-E75E-4B9C-8F07-93A6C7F3292DQ33725213-F7D8134C-00DC-478F-AC74-4CEBEE5B0B77Q33743558-89A71D15-ACE3-47F7-A388-37389C1A9914Q33775256-2C1A0F22-F757-4E59-ACB8-B774935DC949Q33938023-4040609C-A77E-4366-B096-204B02D630C1Q33985947-678BA37E-46FE-4BE9-B791-52F63C0C8F3BQ34057996-BF153A34-0807-494F-A7B0-B04D4DF172E3Q34077069-E69C81C3-8CB1-40BF-9353-2BF752D2D30AQ34142406-0DE251C3-2AC4-4383-8DEB-6F4412FD6F64Q34301547-BF9A2EB9-7011-4198-B74B-96EAB19CA5EBQ34335236-BF324C60-FF0E-4430-AB29-EAED4723A212Q34338060-7C5801F2-C235-4BA3-805B-164241C3C804Q34481647-0F04A166-235C-472A-86CA-EFF1D63B4583Q34505582-5FDC404B-4D9A-4611-B55F-09BD687AACAE
P2860
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Flucytosine: a review of its p ...... toxicity and drug interactions
@ast
Flucytosine: a review of its p ...... toxicity and drug interactions
@en
Flucytosine: a review of its p ...... toxicity and drug interactions
@nl
type
label
Flucytosine: a review of its p ...... toxicity and drug interactions
@ast
Flucytosine: a review of its p ...... toxicity and drug interactions
@en
Flucytosine: a review of its p ...... toxicity and drug interactions
@nl
prefLabel
Flucytosine: a review of its p ...... toxicity and drug interactions
@ast
Flucytosine: a review of its p ...... toxicity and drug interactions
@en
Flucytosine: a review of its p ...... toxicity and drug interactions
@nl
P3181
P356
P1476
Flucytosine: a review of its p ...... toxicity and drug interactions
@en
P2093
P304
P3181
P356
10.1093/JAC/46.2.171
P407
P577
2000-08-01T00:00:00Z